Table 4.
EGF-sensitive hepatic phosphoproteins involved in inflammation, fibrosis, and cell death.
| Protein | Phosphosite(s) | EGF effect |
|---|---|---|
| RIPK1 | S313 | Increased |
| AIFM1 | S581/S267 | Increased/ Decreased |
| BCL2L13 | T342 | Decreased |
| BCLF1 | S177/S529/S656 | Increased/ Decreased/Decreased |
| BNIP3 | S88 | Decreased |
| PDCD4 | S457 | Increased |
| STAB2 | S2503 | Decreased |
| MEF2C | S285 | Decreased |
Note: “EGF Effect” refers to the expression of the relevant phosphorylated protein in mice injected with EGF ( IP) vs. those injected with saline followed by liver extraction within 30 min and hepatic phosphoproteomic analysis. AIFM1, apoptosis inducing factor mitochondria associated 1; BCL2L13, BCL2 like 13; BCLF1, BCL2 associated transcription factor 1; BNIP3, BCL2 interacting protein 3; EGF, epidermal growth factor; IP, intraperitoneal; MEF2C, myocyte enhancer factor 2c; Min, minutes; PDCD4, programmed cell death protein 4; RIPK1, receptor interacting serine/threonine kinase 1; STAB2, stabilin-2.